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Comparison of thyroid transcription factor-1 expression by two monoclonal antibodies 
in schwannomas: the chosen clone matters 
 
To the editor: 
We have read with great interest the recently published study by Wang et al [1] on 
aberrant expression of thyroid transcription factor-1 (TTF-1) in schwannomas. The authors 
described nuclear TTF-1 in 109 (67.7%) schwannomas, including 102 of 132 (77.9%) 
conventional, 1 of 20 (5%) cellular and 6 of 10 (60%) plexiform schwannomas. Nuclear 
staining was not identified in normal peripheral nerves and non-schwannoma peripheral 
nervous system lesions.  
However, the authors used in this study the monoclonal anti−TTF-1 antibody clone 
SPT24 and did not explore the difference between the SPT24 clone (Leica/Novocastra) and 
the other main commercially available anti−TTF-1 antibody clone, 8G7G3/1 (Dako). There is 
strong evidence in the literature that an important factor influencing the prevalence of TTF-1 
expression in tumors (other than those of pulmonary or thyroid origin) is the type of clone that 
is used [2,3]. This has also been demonstrated in publications documenting TTF-1 
immunoreactivity in glial neoplasms [4,5], gynecologic carcinomas [6], breast carcinomas [3] 
and colorectal carcinomas [7,8].  
Therefore, we analyzed TTF-1 expression in 60 additional schwannomas (including 44 
conventional and 13 cellular subtypes) and compared the results obtained with the 8G7G3/1 
and SPT24 TTF-1 clones (see Table 1 and Table 2). We also included in our study 3 cases of 
epithelioid schwannoma, a rare subtype of schwannoma, which was not tested in the current 
study by Wang et al [1]. We used the same combined scoring system to evaluate the intensity 
and distribution of nuclear TTF-1 staining as described by Wang et al. Notably, the SPT24 
clone detected a much higher number of positive cases in both the conventional and cellular 
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subtypes. In conventional schwannomas, positivity with the SPT24 clone was detected in 37 
of 44 (83%) cases as opposed to the 8G7G3/1 clone, which showed expression in 25 of 44 
(56%) cases. With the SPT24 clone, strong and diffuse SPT24 staining for TTF-1 (score 8-9) 
was observed in 14 (44%) conventional schwannomas. On the contrary, none of the cases 
showed a diffuse and strong staining with the 8G7G3/1 clone, and in most of the 8G7G3/1-
positive cases only focal and weak staining (score 2 to 5) was seen. Eight of 13 (61%) and 3 
of 13 (23%) cellular schwannoma cases were only focally and weakly positive with the 
SPT24 and 8G7G3/1 clone, respectively. Compared to the results of Wang et al, we observed 
SPT24 anti−TTF-1 clone positivity in a higher percentage of cellular schwannoma cases. 
However, all positive cases of cellular schwannoma in our study showed only very focal and 
weak positivity (scores 2-3). Three epithelioid schwannomas, tested with both anti−TTF-1 
antibody clones, were completely negative. 
In summary, this comparative study of TTF-1 expression in schwannomas by two 
widely used anti−TTF-1 antibody clones, 8G7G3/1 and SPT24, showed TTF-1 expression 
with both clones, albeit expression with the 8G7G3/1 clone was seen in a much lower 
percentage of cases and was weaker in intensity and more focal in distribution compared to 
the SPT24 staining. With both antibody clones, TTF-1 expression was more prevalent in 
conventional schwannomas and was not seen in the rare epithelioid subtype. These findings 
further underscore the literature data that the sensitivity and specificity of TTF-1 staining is 
dependent on the antibody clone used [3,9]. 
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Table 1 TTF-1 expression in conventional schwannomas 
TTF-1 
expression 
Wang et al [1] Ghent study 
SPT24-clone, n (%) SPT24-clone, n (%) 8G7G3/1-clone, n (%) 
Negative 29/131 (22%) 7/44 (17%) 19/44 (44%) 
Weak 31/131 (24%) 12/44 (27%) 20/44 (45%) 
Moderate 45/131 (34%) 11/44 (25%) 5/44 (11%) 
Strong 26/131 (20%) 14/44 (31%)
a
 0/44 (0%) 
a
Eleven of the 14 strongly staining cases had score 8 
.
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Table 2 TTF-1 expression in cellular schwannomas 
TTF-1 
expression 
Wang et al [1] Ghent study 
SPT24-clone, n (%) SPT24-clone, n (%) 8G7G3/1-clone, n (%) 
Negative 19/20 (95%) 5/13 (39%) 10/13 (77%) 
Weak 1/20 (5%) 8/13 (61%)
a
 3/13 (23%) 
Moderate 0/20 (0%) 0/13 (0%) 0/13 (0%) 
Strong 0/20 (0%) 0/13 (0%) 0/13 (0%) 
a
Five of the 8 weakly staining cases had a low score of 2 or 3 
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